Rajesh Kataria, DO
Rheumatology · Wheelersburg, OHNPI 1619072188
Payments from drug & device makers
Across 1,617 payments — averaging $100.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$97K
- Bristol Myers Squibb$25K
- AbbVie$11K
- Medexus Pharma, Inc.$10K
- Cardinal Health 108 LLC$3K
- Pfizer$3K
- plus $13K from 32 others
What the payments were for
- Consulting fees$8,4065%
- Speaking & faculty fees$106,37166%
- Grants$2400%
- Travel & lodging$20,18412%
- Food & beverage$26,57716%
- Education$3780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 496 | $96,709 |
| Bristol Myers Squibb | 72 | $25,223 |
| AbbVie | 198 | $10,601 |
| Medexus Pharma, Inc. | 20 | $9,981 |
| Cardinal Health 108 LLC | 14 | $3,334 |
| Pfizer | 101 | $3,068 |
| Johnson & Johnson | 72 | $2,203 |
| Novartis | 108 | $2,027 |
| UCB, Inc. | 135 | $1,896 |
| E.r. Squibb & Sons, L.L.C. | 80 | $1,108 |
| Lilly USA, LLC | 62 | $1,017 |
| AstraZeneca(2 entities) | 48 | $874 |
| GSK | 51 | $818 |
| ANI Pharmaceuticals, Inc. | 18 | $629 |
| Mallinckrodt Hospital Products Inc. | 19 | $458 |
| Janssen Scientific Affairs, LLC | 10 | $386 |
| Radius Health, Inc. | 17 | $304 |
| Genentech USA, Inc. | 20 | $258 |
| Mallinckrodt Enterprises LLC | 18 | $183 |
| Aurinia Pharma U.S., Inc. | 5 | $137 |
| Bioventus LLC | 7 | $127 |
| Sanofi | 6 | $121 |
| Boehringer Ingelheim | 6 | $120 |
| Regeneron Healthcare Solutions, Inc. | 6 | $106 |
| Antares Pharma, Inc. | 6 | $105 |
| Sobi, Inc | 5 | $97 |
| Organon | 5 | $50 |
| Invivyd Inc | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Ascend Therapeutics US, LLC | 2 | $23 |
| Assertio Therapeutics, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Mylan Institutional Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,154 in reported general payments places this provider in the 90th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel MiniEtanercept | 48 | $350,244 |
| OtezlaApremilast | 62 | $334,040 |
| Humira(Cf)Adalimumab | 25 | $256,992 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $221,821 |
| Cosentyx Unoready PenSecukinumab | 16 | $207,359 |
| RinvoqUpadacitinib | 29 | $189,274 |
| Orencia ClickjectAbatacept | 27 | $152,819 |
| Enbrel SureclickEtanercept | 20 | $144,733 |
| Humira(Cf) PenAdalimumab | 17 | $124,191 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $105,186 |
| KevzaraSarilumab | 23 | $98,370 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $94,168 |
| EnbrelEtanercept | 13 | $90,740 |
| Taltz AutoinjectorIxekizumab | 13 | $88,484 |
| Taltz SyringeIxekizumab | 12 | $84,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel, Prolia | $96,709 | $461,15896 claims |
| AbbVieHumira(Cf), Rinvoq | $10,601 | $446,26654 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,896 | $105,18615 claims |
| SanofiKevzara | $121 | $98,37023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Wheelersburg
- Isam DiabMiddleburg Hts$15.3M
- Sanford WolfeDayton$4.7M
- Jeffrey ChaitoffSolon$3.7M
- Nora SingerCleveland$3M
- Chacko AlappattMiamisburg$2M
- Leonard CalabreseCleveland$1.9M
- Jisna PaulHilliard$1.9M
- Carol LangfordCleveland$1.8M
- Gregory DelorenzoCincinnati$1.3M
- Michael LuggenCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.